{"filings":[{"id":862676,"accession_number":"0001683168-26-004565","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-06-04T20:49:48+00:00","items":["5.07"],"status":"ready","headline":"Aclarion stockholders elect seven directors, ratify auditor, approve equity plan amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; votes for ranged from 468,385 to 533,055; broker non-votes 841,750.","Ratification of Haynie & Company as auditor: 1,588,388 for, 20,623 against, 10,985 abstain.","Amendment to 2022 equity incentive plan approved: 453,431 for, 323,512 against, 1,302 abstain; broker non-votes 841,751."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94257,"accession_number":"0001683168-26-003124","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aclarion authorizes $2.5 million share repurchase program over 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $2.5M in common stock over next 12 months.","CEO Brent Ness says current valuation does not reflect full strength of Nociscan platform.","Company had $19.0M cash as of March 31, 2026; repurchase funded from existing cash.","Program may be executed via open market purchases, block trades, 10b5-1 plans, or private deals.","Management believes cash runway supports milestones including CLARITY trial initial milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106475,"accession_number":"0001683168-26-002024","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Aclarion adopts one-year stockholder rights plan with 10% trigger","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board unanimously adopted Rights Plan effective March 19, 2026, expiring March 18, 2027.","Under the plan, one Right per share (including warrants); exercise price $14.00 per Right.","Trigger at 10% beneficial ownership; existing holders >10% grandfathered but cannot increase ownership.","Upon trigger, holders (except acquirer) can buy shares worth 2x exercise price; Board may redeem at $0.001 per Right.","Company states plan not adopted in response to any specific takeover proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106474,"accession_number":"0001683168-26-000241","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclarion closes $10.4M equity offering, reports $21.6M cash, zero debt, runway into 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed $10.4M common-stock-only offering at $5.18/share; includes 200,000 shares and pre-funded warrants for 1.8M shares.","Cash balance $21.6M as of Jan 12, 2026; zero debt.","Cash runway extended into 2028 based on current operating plans.","Plans to accelerate CLARITY trial enrollment, launch Nociscan v2.8 in Q1'26, and pursue payer coverage.","Dawson James Securities acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106473,"accession_number":"0001683168-26-000168","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion raises ~$10.36M via registered direct offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["200,000 shares at $5.18 each; pre-funded warrants for 1.8M shares at $0.00001 exercise price.","Gross proceeds ~$10.36M; net to fund market development, Clarity Trial, product dev, and G&A.","Pre-funded warrants immediately exercisable with 4.99%/9.99% beneficial ownership limitation.","Closing expected Jan 9, 2026; Dawson James Securities is placement agent at 6.0% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122822,"accession_number":"0001683168-25-007516","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion raises ~$2.5M via registered direct offering of stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 64,000 common shares and 236,000 pre-funded warrants at $8.36/share; gross proceeds ~$2.5M.","Pre-funded warrants have $0.00001 exercise price, exercisable immediately until fully exercised.","Proceeds to fund market development, The Clarity Trial, product development, and general corporate purposes.","Offering expected to close on October 14, 2025; placement agent fee is 7.0% of gross proceeds.","Dawson James Securities acts as exclusive placement agent for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139516,"accession_number":"0001683168-25-006659","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Aclarion appoints Greg Gould as CFO; John Lorbiecki retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory A. Gould appointed CFO effective September 1, 2025, succeeding retiring John Lorbiecki.","Gould receives $262,500 base salary, annual bonus up to 50% of base at board discretion.","Inducement stock option for 17,000 shares at $7.15; vests 25% in one year, remainder monthly over three years.","Gould has raised over $450M in debt/equity, led 10+ acquisitions, and served as CFO at 7 public companies.","Lorbiecki will stay in a non-CFO role through October 1, 2025 to assist transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139515,"accession_number":"0001683168-25-005246","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclarion shareholders approve reverse stock split, reject equity plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected with 47,374 to 51,347 votes for; broker non-votes of 200,431.","Ratification of Haynie & Company as auditor approved: 241,005 for, 23,143 against.","Reverse stock split proposal approved: 177,593 for, 87,330 against, 2,124 abstain.","Amendment to 2022 equity incentive plan rejected: 29,621 for, 35,466 against, 1,527 abstain, with 200,431 broker non-votes.","Annual meeting was adjourned from July 7, 2025, and reconvened on July 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139514,"accession_number":"0001683168-25-004952","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Aclarion adjourns annual meeting to July 21 to solicit additional votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting convened then adjourned without business on July 7, 2025.","Reconvened Monday, July 21, 2025 at 9:30 a.m. MT at 8181 Arista Place, Broomfield CO.","Adjournment to solicit more votes on proposals in May 13 proxy statement.","Record date remains May 9, 2025; prior proxies carry forward unless revoked.","Stockholders urged to vote by 11:59 p.m. MT July 20, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157085,"accession_number":"0001683168-25-004669","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO John Lorbiecki to retire; replacement search underway, expected by Q3 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Lorbiecki notified retirement on June 16, 2025; will stay to transition duties.","Company initiated search for new CFO; expects appointment before end of Q3 2025.","Lorbiecki joined as CFO in October 2021, prior to April 2022 IPO.","Retirement not due to any disagreement on controls, financials, or audit matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157084,"accession_number":"0001683168-25-002738","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclarion updates investor deck: $14.6M cash, UK payer approvals, CLARITY trial on track for interim Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash on hand ~$14.6M as of Apr 9 2025 10-K; runway into Q3 2026; zero debt, no preferred shares, no near-term warrant overhang.","Secured UK payer approvals: three of top four private medical insurers now cover Nociscan, representing 5.2M people.","Pivotal CLARITY trial fully funded ($4.6M total); first patient estimated Q2 2025; interim results expected Q2 2026.","Expanded U.S. physician referral and commercial support; CPT Category III codes 0609T/0611T in place; Nociscan list price $1,450 vs discogram $2,000-$5,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175457,"accession_number":"0001683168-25-001987","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Aclarion effectuates 1-for-27 reverse stock split; shares reduce from ~15.72M to ~582K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-27 ratio effective 5:00 p.m. ET on March 27, 2025; split-adjusted trading commenced March 28.","Outstanding common shares reduced from ~15.72M pre-split to ~582,000 post-split; authorized shares remain 200 million.","No fractional shares issued; any fractional holdings rounded up to one whole share at participant level with DTC.","Warrants, stock options, and restricted stock units adjusted proportionally; exercise prices adjusted per terms.","Board previously approved split ratio range of 1-for-5 to 1-for-50; final 1-for-27 ratio set in March 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175456,"accession_number":"0001683168-25-001566","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aclarion reports $15.2M cash, regains Nasdaq equity compliance; 87% of Series B warrants exercised","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Current cash balance ~$15.2M; company in compliance with Nasdaq stockholders' equity rule of $2.5M minimum.","Since March 6, ~87% of Series B warrants exercised via cashless ACE feature, issuing ~12.7M common shares.","Total shares outstanding ~13.7M as of March 12, 2025; no Series A warrants exercised to date.","Series A warrants have adjusted exercise price of $6.70 (above current market) and lack ACE feature.","Company may implement a future reverse stock split to meet Nasdaq $1.00 minimum bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175455,"accession_number":"0001683168-25-001373","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclarion stockholders approve share issuance and authorized share increase at special meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Issuance Proposal: 3,750,201 for, 383,538 against, 6,225 abstentions; approved.","Charter Amendment Proposal to increase authorized common stock to 300M shares: 7,008,009 for, 1,622,299 against, 26,715 abstentions; approved.","Adjournment Proposal: 7,425,910 for, 1,104,548 against, 126,563 abstentions; approved.","Approximately 42% of outstanding shares represented at meeting, constituting quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175454,"accession_number":"0001683168-25-001288","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-02-28T23:59:59+00:00","items":["5.07","7.01","9.01"],"status":"ready","headline":"Aclarion adjourns special meeting to March 5 to solicit additional votes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special Meeting convened Feb 28, 2025, adjourned without transacting any business.","Reconvened on Wednesday, March 5, 2025 at 9:30 a.m. Mountain Time at Broomfield office.","Record date for voting remains January 6, 2025; proxies previously submitted remain valid.","Meeting adjourned to solicit additional votes on proposals described in Feb 3 proxy statement.","Stockholders can change votes until 11:59 p.m. MT on March 4, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175453,"accession_number":"0001683168-25-000627","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aclarion prices $4.7M registered direct offering of 506,803 shares at $9.25 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$4.7M; 506,803 shares at $9.25/share; closing expected Jan 31, 2025.","Net proceeds to fund market development, clinical evidence, product development, and G&A.","Dawson James Securities serving as sole placement agent; offering under effective S-3 shelf.","Offering priced at the market; no change to previously announced business plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175452,"accession_number":"0001683168-25-000612","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Aclarion effects 1-for-335 reverse stock split; regains Nasdaq equity compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective Jan 29, 2025 at 1:335 ratio; shares reduced from ~169.4M to ~500,000.","Public offering closed Jan 16 with gross proceeds of ~$14.55M, boosting stockholders' equity.","Company expects stockholders' equity of ~$10.5M as of Jan 30, regaining Nasdaq minimum equity compliance.","Outstanding warrants, options, and RSUs adjusted proportionally; no fractional shares issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175451,"accession_number":"0001683168-25-000431","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-01-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion closes ~$13.3M net equity/warrant offering; proceeds to redeem Series B preferred, fund growth","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds of ~$13.3M from offering of 100K shares, ~144M pre-funded warrants, and Series A & B warrants.","Offering priced at $0.10 per unit (share + two warrants); underwriter Dawson James Securities.","Proceeds to redeem all outstanding Series B Preferred Stock at $1,000/share plus accrued dividends.","Remaining proceeds for product platform build-out, sales/marketing, and general corporate purposes.","90-day lock-up agreements for directors/officers; company restrictions on further issuances until after stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175450,"accession_number":"0001683168-25-000099","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aclarion prices registered direct offering of 3.38M shares at $0.142/share for ~$480K gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pricing: 3,380,276 shares at $0.142 per share; gross proceeds ~$480,000 before fees and expenses.","Expected close on or about January 6, 2025; offering is a registered direct offering priced at the market.","Net proceeds to fund market development, clinical evidence, product development, G&A, and general corporate purposes.","Dawson James Securities serving as sole placement agent; cash fee of 7% of aggregate gross proceeds.","Offering made under effective shelf registration on Form S-3 (File No. 333-281999)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175449,"accession_number":"0001683168-25-000059","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Aclarion terminates $10M ATM sales agreement with Ascendiant Capital Markets, effective Jan 3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC on January 3, 2025.","Agreement allowed sale of up to $10M of common stock; only 1,606,211 shares for ~$0.3M gross proceeds were sold.","ATM facility is no longer available for future capital raises.","Original agreement was entered into on September 24, 2024, and filed as Exhibit 1.1 to prior Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175448,"accession_number":"0001683168-25-000056","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2025-01-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclarion shareholders approve all 7 proposals at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven directors elected, each receiving >1.1M votes for (no broker-non-votes excluded).","Ratification of auditor Haynie & Company: 3,776,879 for, 250,987 against.","Reverse stock split approved: 3,006,776 for, 1,016,688 against.","Issuance of shares under equity line, Series B and C preferred stock proposals all approved.","Amendment to 2022 equity incentive plan also approved (1,074,285 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192407,"accession_number":"0001683168-24-008424","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aclarion amends equity line with White Lion, adds Accelerated & Pre-Market purchase notices, extends to Dec 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity line expiration extended from Dec 31, 2024 to Dec 31, 2025.","Two new purchase methods added: Accelerated Purchase Notice (85% of lowest traded price over 1 hour) and Pre-Market Purchase Notice (lowest pre-market price).","White Lion receives 560,915 Commitment Shares valued at $100,000 as consideration for the amendment.","Amendment is subject to stockholder approval under Nasdaq listing rules if required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192406,"accession_number":"0001683168-24-007100","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-10-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aclarion receives Nasdaq delisting notice for bid price; hearing held Oct 10","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Oct 8 notice of non-compliance with $1 bid price requirement for Nasdaq Capital Market.","Also not compliant with stockholders' equity rule; reported equity of $1.64M vs. $2.5M minimum.","Panel hearing occurred Oct 10; delisting stayed pending written decision.","Shareholders approved reverse stock split (1:5 to 1:50) to regain compliance.","Company intends to implement reverse split in near future to meet bid price rule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192405,"accession_number":"0001683168-24-006791","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aclarion raises $1.0M via Series C convertible preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $1.0M from sale of 1,000 shares of Series C Preferred Stock at $1,000/share, convertible at $0.1759 per share.","Issued warrants for 5,685,049 shares of common stock at $0.1759 exercise price, 5.5-year term.","Series C Preferred Stock carries 10% annual dividend payable quarterly, with option to pay in stock or capitalize.","Conversion price subject to anti-dilution full-ratchet on dilutive issuances; trigger events increase dividend to 18% and reduce price to 80% of lowest VWAP.","Proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208872,"accession_number":"0001683168-24-006627","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-09-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion enters ATM equity agreement to sell up to $10M common stock, initial $1.075M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM issuance sales agreement with Ascendiant Capital Markets for up to $10M of common stock.","Initial prospectus supplement caps sales at $1.075M due to Form S-3 General Instruction I.B.6.","Agent commission of 3.0% of gross proceeds; Company may suspend or terminate at any time.","Sales will be made under effective shelf registration statement (333-281999) declared effective Sept 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208871,"accession_number":"0001683168-24-006598","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclarion stockholders approve reverse stock split of 1:5 to 1:50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split with 2,050,165 For, 1,133,449 Against, 583,616 Abstain.","Board granted discretion to set ratio between 1-for-5 and 1-for-50.","Reverse split, if implemented, must be completed within one year of approval.","No broker non-votes were reported for the proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208870,"accession_number":"0001683168-24-006107","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aclarion raises $290k via 1M share offering at $0.29; also issues warrants for 400k shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,000,000 shares at $0.29/share for gross proceeds of $290,000.","Also issued warrants to purchase up to 400,000 shares at $0.29, exercisable from Feb 27, 2025 for 5 years.","Shares offered under Regulation A; warrants under Section 4(a)(2) exemption.","No placement agent fees or commissions on the transaction.","Company may raise additional up to ~$29.39M on same terms, but no current agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208869,"accession_number":"0001683168-24-006005","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aclarion receives Nasdaq delisting notice for stockholders' equity shortfall","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Aclarion it fails minimum $2.5M stockholders' equity requirement, reporting $1.64M as of June 30, 2024.","Company has until August 29, 2024 to appeal; otherwise trading suspension begins September 3, 2024.","Aclarion intends to request a hearing to stay any suspension and will evaluate options to regain compliance.","Nasdaq letter does not affect Aclarion's business operations or SEC reporting requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208868,"accession_number":"0001683168-24-005844","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aclarion exchanges $930K of near-maturing notes for Series B Preferred convertible at $0.234/share","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $930,000 of principal and accrued interest on notes due Sept 2024 for 930 Series B Preferred shares at $1,000 each.","Series B Preferred converts at $0.234 per share, with full-ratchet anti-dilution on future below-conversion-price issuances.","Preferred pays 10% annual dividends (cash or stock at company option) and ranks senior to common upon liquidation.","Conversion capped at 4.99% beneficial ownership (holder may raise to 9.99% on 61-day notice).","Company may redeem at 125% of liquidation value; triggering events (bankruptcy, Nasdaq noncompliance) raise dividend to 18% and lower conversion price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208866,"accession_number":"0001683168-24-005512","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K/A","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion sells 400k shares at $0.29, raising $116k; may raise up to $29.68M more","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 400,000 shares of common stock at $0.29 per share for gross proceeds of $116,000.","Shares offered at-the-market under Nasdaq rules via existing Form 1-A offering statement.","No placement agent or commissions paid on the transaction.","Company retains ability to raise up to ~$29.68M additional on same terms but no commitments exist.","This 8-K/A corrects a clerical error in the exhibit attached to the original August 12 filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208867,"accession_number":"0001683168-24-005494","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion raises $116K via sale of 400K shares at $0.29 per share to institutional investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 400,000 shares of common stock at $0.29/share for gross proceeds of $116,000.","Shares sold under qualified Form 1-A Offering Statement; no placement agent or commissions.","Company may raise up to $29.68M additional on same terms, but no current agreements exist.","Proceeds from the at-the-market offering will support general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226677,"accession_number":"0001683168-24-004470","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aclarion gets first payer coverage for Nociscan from AXA in Greater London","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["AXA is the 2nd largest private medical insurer in the UK with ~30% market share and ~3M insured customers.","This is the first insurance company to approve payment for Nociscan; CEO calls it the most significant milestone to date.","Coverage applies to Greater London in conjunction with The London Clinic; self-pay/private insurance represents ~70% of UK private hospital revenues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226676,"accession_number":"0001683168-24-004321","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aclarion amends bylaws to reduce stockholder meeting quorum from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amendment on June 12, 2024; quorum reduced to holders of one-third of voting power from a majority.","Company cited past difficulties reaching quorum due to dispersed stockholder base and broker elimination of discretionary voting.","Lower quorum requirement aims to avoid meeting adjournments, additional costs, and management distractions.","Full text of the amendment filed as Exhibit 3.1 to this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226675,"accession_number":"0001683168-24-002760","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-04-29T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Aclarion raises $304,500 via equity line, shares outstanding increase to 8.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed on $304,500 in new capital by selling 1.05M shares under existing equity line facility.","Total outstanding shares increased to 8,203,500 as of April 26, 2024.","Obtained limited waiver from February 27, 2024 public offering agreements to enable the transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226674,"accession_number":"0001683168-24-002343","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aclarion receives Nasdaq notice of non-compliance with minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 8, 2024 for failing minimum bid price of $1.00 per share over 30 consecutive business days.","Has 180 calendar days (until October 7, 2024) to regain compliance by having bid price close at or above $1.00 for 10 consecutive days.","May be eligible for an additional 180-day period if it meets other listing requirements and intends to effect a reverse stock split if needed.","Company intends to monitor bid price and consider options to regain compliance; delisting is not immediate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245644,"accession_number":"0001683168-24-001196","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Aclarion closes $3.0M public offering; believes it regains Nasdaq equity compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed public offering of 5,175,000 units at $0.58/unit; gross proceeds ~$3.0M before expenses.","Each unit includes one share (or prefunded warrant at $0.00001) plus two common warrants exercisable at $0.58 for 5 years.","Proceeds to repay debt, build product platforms, expand sales/marketing, and for general corporate purposes.","Company believes it now has stockholders' equity of at least $2.5M, curing prior Nasdaq minimum equity non-compliance.","Offering closed on Feb 27, 2024; Maxim Group LLC acted as placement agent with 7% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245643,"accession_number":"0001683168-24-001102","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Aclarion posts $4.9M net loss in FY2023; auditor flags going concern doubt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.9M in FY2023 vs $7.1M in FY2022; revenue $75,404, up 25% from $60,444.","Operating expenses $4.9M (FY2023) vs $5.6M (FY2022); cash used in ops $3.6M.","Cash and equivalents $1.0M at Dec 31, 2023; accumulated deficit $44.3M.","Auditor Haynie & Co. expresses substantial doubt about ability to continue as going concern.","FY2022 financials restated to correct misstatements; 1-for-16 reverse stock split effective Jan 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":75404.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245642,"accession_number":"0001683168-24-000519","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-01-29T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Aclarion exchanges ~$1.19M debt for 500k shares, boosting share count to 1.79M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["From Jan 23–26, 2024, Aclarion entered exchange agreements with accredited investors to swap debt for equity.","Issued 500,000 shares of common stock to retire approximately $1,185,226 of principal and accrued interest on notes.","Outstanding shares increased to 1,791,375 as of January 26, 2024.","Future exchanges of notes for common stock are possible but not currently agreed upon.","Shares were issued in unregistered transactions under Section 3(a)(9) and 4(a)(2) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245641,"accession_number":"0001683168-24-000377","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-01-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aclarion exchanges $157K of notes for 56K shares at $2.8101 per share","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $157,365.60 of principal and accrued interest on unsecured notes for 56,000 common shares at $2.8101/share.","Shares issued without restricted legend under Section 3(a)(9) and Section 4(a)(2) exemptions.","Future exchanges may occur on similar terms but no definitive agreements exist at this time.","Transaction reduces debt and increases outstanding share count, no impact on operations or guidance.","Form of Exchange Agreement filed as Exhibit 10.1, detailing terms and representations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245640,"accession_number":"0001683168-24-000066","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Aclarion effectuates 1-for-16 reverse stock split; shares reduce to ~840K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective January 3, 2024, every 16 shares of common stock combined into 1 share; no fractional shares issued.","Pre-split shares decreased from ~13.4M to ~840,000 post-split; authorized shares remain 200M.","Outstanding warrants, stock options, and RSUs adjusted proportionately; exercise prices also adjusted.","Board and stockholders had approved a reverse split range of 1-for-5 to 1-for-50; final ratio of 1-for-16 set in January 2024.","Common stock began trading on split-adjusted basis on Nasdaq at market open on January 4, 2024; new CUSIP 655187201."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263109,"accession_number":"0001683168-23-008961","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aclarion holds 2023 Annual Meeting; all director nominees elected, auditor ratified, equity line approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven directors elected with ~3.5M votes for each; broker non-votes ~1.63M.","Ratification of Haynie & Company as auditor: 5,055,198 for, 150,382 against, 14,553 abstain.","Approval of shares issuance under equity line passed: 3,552,160 for, 40,372 against, 708 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263108,"accession_number":"0001683168-23-008420","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aclarion closes $250K unsecured note financing with 8% interest and warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Gross proceeds of $250,000 from accredited investors via unsecured non-convertible notes.","Notes have $294,117.65 principal (15% OID), 8% interest, mature April 19, 2024.","Issued 744,890 warrants with $0.2865 exercise price, 5-year term, full ratchet anti-dilution.","Issued 148,978 commitment shares and 25,210 pre-funded warrants to placement agent.","Proceeds for general corporate purposes; registration rights for resale of securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263107,"accession_number":"0001683168-23-007017","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aclarion enters $10M common stock purchase agreement with White Lion Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $10M aggregate gross purchase of newly issued common stock at discounts of 85-95% of VWAP.","Company issued 187,500 commitment shares ($75,000 value) to White Lion.","Purchase right runs until Dec 31, 2024; per-notice limit capped at $1M or 30% of daily volume.","Registration rights agreement filed; shares to be registered for resale within 30 days.","Funds to be used for general corporate purposes; no specific use cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280326,"accession_number":"0001683168-23-006784","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aclarion updates investor deck; highlights CLARITY trial start Q4 2023 with 300 patients","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["CLARITY prospective randomized trial begins Q4 2023; 300 patients, 42-month timeline, Johns Hopkins anchor site.","NIH BACPAC studies (comeBACK, BEST) using Nociscan; enrollment ongoing, expected completion Q2 2024.","CPT Category III codes 0609T and 0611T secured Jan 2021; early commercialization in progress.","39 issued US/international patents plus 13 pending; market opportunity up to $135B low back pain market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280325,"accession_number":"0001683168-23-006328","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aclarion receives Nasdaq delisting notice for equity shortfall; appeals to hearings panel","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq staff determined to delist common stock on Aug 31, 2023 for failure to meet $2.5M stockholders' equity requirement.","Company had 180-day extension until Aug 30, 2023 to regain compliance but did not meet terms.","Company requested hearing before Nasdaq Panel; trading stay pending written decision.","Also not compliant with $1.00 bid price requirement; grace period runs through Jan 31, 2024.","Delisting could reduce liquidity, market price, and access to financing; no assurance of favorable outcome."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280324,"accession_number":"0001683168-23-006219","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aclarion closes $750K second tranche of unsecured note financing; amends terms","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Received $750K gross proceeds from second tranche; principal amount $862.5K (15% OID).","Notes carry 8% interest, mature May 16, 2024, unsecured and non-convertible.","Monthly interest payments waived until maturity; prepayment allowed without penalty.","Company must use 50% of proceeds from offerings over $4M to retire outstanding notes.","Amendment waives warrant anti-dilution for shares under equity line with White Lion Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280323,"accession_number":"0001683168-23-006201","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-08-31T23:59:59+00:00","items":["3.01","4.01","9.01"],"status":"ready","headline":"Aclarion regains Nasdaq compliance after late 10-Q; auditor resigns, Haynie & Company appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Q2 2023 Form 10-Q on Aug 25; Nasdaq confirmed compliance with Listing Rule 5250(c)(1) on Aug 28.","CohnReznick resigned as auditor effective Aug 25; cited material weaknesses in internal control over financial reporting as of Mar 31 and Jun 30, 2023.","Appointed Haynie & Company as new independent auditor on Aug 29, 2023, for fiscal year 2023.","No disagreements with CohnReznick on accounting principles; resignation was not requested by the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280322,"accession_number":"0001683168-23-006083","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["2.02","8.01","3.01","9.01"],"status":"ready","headline":"Aclarion files delayed Q2 10-Q after Nasdaq notice; believes compliance regained","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on August 23, 2023 for non-compliance with Listing Rule 5250(c)(1) due to late 10-Q.","Delay caused by completion of review process by new independent accountant CohnReznick LLP.","Filed the delinquent Quarterly Report for Q2 2023 on August 25, 2023.","Company believes it has regained compliance; Nasdaq notice had no immediate effect on trading.","If not resolved, company would have had until October 22, 2023 to submit a compliance plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280321,"accession_number":"0001683168-23-005758","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Aclarion waives monthly interest on $1.44M notes, defers all interest to maturity","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Waived monthly interest on $1.23M (Cavalry Fund) and $208K (WVP) unsecured non-convertible notes.","Interest now payable in arrears only on Maturity Date; waiver retroactive to May 16, 2023.","Company retains option to draw $750K second tranche through Nov 16, 2023.","Company to reimburse $5,000 legal fee to lead holder's counsel.","No change to principal amount; notes continue to bear interest at original rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280320,"accession_number":"0001683168-23-005523","cik":1635077,"company_name":"Aclarion, Inc.","ticker":"ACON","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aclarion receives Nasdaq notice for non-compliance with $1.00 minimum bid price requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice dated Aug 4, 2023, due to closing bid price below $1.00 for 30 consecutive business days through Aug 3, 2023.","Company has 180 calendar days to regain compliance by closing at or above $1.00 for ten consecutive business days.","If not cured, may be eligible for additional 180 days if meeting market value of publicly held shares and other listing requirements.","Company intends to monitor bid price and consider options including a reverse stock split if necessary.","Notice does not affect business operations or SEC reporting obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7682220.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-08-10T23:59:59+00:00|280320"}